BR112012024422A2 - uso de novos inibidores pan-cdk para tratamento de tumores - Google Patents

uso de novos inibidores pan-cdk para tratamento de tumores

Info

Publication number
BR112012024422A2
BR112012024422A2 BR112012024422A BR112012024422A BR112012024422A2 BR 112012024422 A2 BR112012024422 A2 BR 112012024422A2 BR 112012024422 A BR112012024422 A BR 112012024422A BR 112012024422 A BR112012024422 A BR 112012024422A BR 112012024422 A2 BR112012024422 A2 BR 112012024422A2
Authority
BR
Brazil
Prior art keywords
cdk inhibitors
treat tumors
new pan
tumors
pan
Prior art date
Application number
BR112012024422A
Other languages
English (en)
Portuguese (pt)
Inventor
Antje Margret Wengner
Gerhard Siemeister
Ulrich Lücking
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112012024422A2 publication Critical patent/BR112012024422A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012024422A 2010-04-01 2011-03-28 uso de novos inibidores pan-cdk para tratamento de tumores BR112012024422A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (de) 2010-04-01 2010-04-01 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
PCT/EP2011/054733 WO2011120922A1 (de) 2010-04-01 2011-03-28 Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
BR112012024422A2 true BR112012024422A2 (pt) 2016-05-31

Family

ID=43858236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024422A BR112012024422A2 (pt) 2010-04-01 2011-03-28 uso de novos inibidores pan-cdk para tratamento de tumores

Country Status (21)

Country Link
US (1) US20130210846A1 (https=)
EP (1) EP2552450A1 (https=)
JP (1) JP5816259B2 (https=)
KR (1) KR20130014678A (https=)
CN (1) CN102834100A (https=)
AU (1) AU2011234654B2 (https=)
BR (1) BR112012024422A2 (https=)
CA (1) CA2794996A1 (https=)
CL (1) CL2012002753A1 (https=)
CR (1) CR20120502A (https=)
DE (1) DE102010014426A1 (https=)
DO (1) DOP2012000260A (https=)
EC (1) ECSP12012198A (https=)
MA (1) MA34098B1 (https=)
MX (1) MX337722B (https=)
NZ (1) NZ602710A (https=)
PH (1) PH12012501945A1 (https=)
SG (2) SG183925A1 (https=)
TN (1) TN2012000469A1 (https=)
UA (1) UA108494C2 (https=)
WO (1) WO2011120922A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2867746A1 (en) * 2012-03-21 2013-09-26 Bayer Intellectual Property Gmbh Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
CN105007945A (zh) * 2013-03-07 2015-10-28 拜耳医药股份有限公司 (rs)-s-环丙基-s-(4-{[4-{[(1r,2r)-2-羟基-1-甲基丙基]氧基}-5-(三氟甲基)嘧啶-2-基]氨基}苯基)亚砜亚胺用于治疗特定肿瘤的用途
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
JP2016526540A (ja) * 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU744986B2 (en) 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
AU2003212282A1 (en) 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CL2012002753A1 (es) 2013-01-18
ECSP12012198A (es) 2012-10-30
CA2794996A1 (en) 2011-10-06
CN102834100A (zh) 2012-12-19
MA34098B1 (fr) 2013-03-05
TN2012000469A1 (en) 2014-01-30
MX337722B (es) 2016-03-16
NZ602710A (en) 2014-05-30
PH12012501945A1 (en) 2017-08-09
SG10201502566SA (en) 2015-05-28
WO2011120922A1 (de) 2011-10-06
JP5816259B2 (ja) 2015-11-18
JP2013523680A (ja) 2013-06-17
EP2552450A1 (de) 2013-02-06
MX2012011427A (es) 2013-03-05
US20130210846A1 (en) 2013-08-15
CR20120502A (es) 2012-11-20
AU2011234654A1 (en) 2012-10-25
UA108494C2 (uk) 2015-05-12
SG183925A1 (en) 2012-10-30
AU2011234654B2 (en) 2015-08-06
KR20130014678A (ko) 2013-02-08
DE102010014426A1 (de) 2011-10-06
DOP2012000260A (es) 2013-03-31

Similar Documents

Publication Publication Date Title
BR112012024422A2 (pt) uso de novos inibidores pan-cdk para tratamento de tumores
PH12017502141A1 (en) Compounds and their methods of use
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
BR112013024502A2 (pt) ciclopropilaminas como inibidores lsd1
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201270149A1 (ru) Ингибиторы bace
EA201300211A1 (ru) N-ацилсульфонамидные промоторы апоптоза
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
BR112015023760A2 (pt) compostos e composições terapêuticas
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
WO2014113407A3 (en) Use of small molecule inhibitors targeting eya tyrosine phosphatase
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201270728A1 (ru) Пуриновые соединения
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
EA201590656A1 (ru) Азаиндолины
BR112015023280A2 (pt) derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]